Navigation Links
New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
Date:5/9/2011

CHICAGO, May 9, 2011 /PRNewswire/ -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population.  The pediatric UC findings, presented today at Digestive Disease Week, showed REMICADE induced clinical response in 73 percent of patients aged 6-17 years at week 8, the primary endpoint of the trial.  REMICADE received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with moderately to severely active UC in September 2005 and in October 2006, REMICADE received FDA approval for maintaining clinical remission and mucosal healing indications in adults living with UC.

UC is a chronic inflammatory bowel disease (IBD) of the colon.  It is estimated that 1.4 million Americans have IBD with the number evenly split between UC and Crohn's disease.  An estimated 150,000 children under age 17 are living with debilitating symptoms of IBD.(1)  

"The results of this study are consistent with findings from the Active Ulcerative Colitis (ACT) trials, which evaluated REMICADE in the treatment of adults with ulcerative colitis," said Jeffrey Hyams, Head of the Division of Digestive Diseases and Nutrition at Connecticut Children's Medical Center and Professor of Pediatrics at University of Connecticut School of Medicine, and lead study investigator.  "UC can be a devastating disease, particularly for children and adolescents.  It is encouraging to see such promising results in a patient population that is in need of additional treatment options."

In December 2010, Centocor Ortho Biotech Inc. submitted a supplemental Biologics License Application (sBLA) to the FDA requesting the approval of REMICADE (infliximab) for the treatment of modera
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Research and Markets has announced the addition of ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to determine the size of a particle in a material ... the size of particles as it can affect the functionality ... determine the behavior and nature of a material, and for ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 "Ischemic ... H2, 2014" provides data on the Ischemic Stroke ... provides elemental information and data relating to the ... , View full global Ischemic Stroke Research Report ... an overview of the trial numbers and their ...
(Date:7/25/2014)... by researchers from the University of Leicester has ... unlocking the potential to create new materials using ... been published in the prestigious academic journal ... technique to examine in rich detail the structure ... containing an acetylene molecule and a single helium ...
(Date:7/25/2014)... San Diego, CA (PRWEB) July 25, 2014 ... “Paws” For Your Pet with Lorry Young will be ... DVM, to talk about stem cell therapy in pets. ... discuss the benefits of stem cell therapy for pets suffering ... developments moving the Regenerative Veterinary Medicine industry forward. , Young ...
Breaking Biology Technology:Global Particle Size Analysis Market 2014-2018 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3
... In chemical terms, nanoparticles have different properties from their big ... relation to their tiny mass and at the same time ... that lead to altered material properties. Ceramics made of nanomaterials ... is gold-coloured while a nanosliver of it is reddish. , ...
... VRNM ), a pioneer in the development and ... that it will release 2010 fourth quarter and year-end financial ... conjunction with the release, the Company will host a conference ... p.m. ET. The call may be accessed by ...
... SAN DIEGO, Feb. 22, 2011 Otonomy, Inc., ... disorders of the ear, today announced positive results ... multiple preclinical models of hearing loss.  Data demonstrated ... a sustained release gel formulation of the corticosteroid ...
Cached Biology Technology:3-D nanoparticle in atomic resolution 2Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results 2Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results 3Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 2Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 3
(Date:7/27/2014)... global climate change to cut food supplies. But these ... between increasing temperature and air pollution specifically ozone ... new study involving researchers at MIT shows that these ... to take both warming and air pollution into account ... detail at global production of four leading food crops ...
(Date:7/27/2014)... have identified more than two dozen genetic risk ... had not been previously reported. The study, published ... by the National Institutes of Health (NIH) and ... "Unraveling the genetic underpinnings of Parkinson,s is vital ... complex disease, and hopefully, may one day lead ...
(Date:7/25/2014)... from the Terra satellite show the different areas that have ... Russia. The burn scars show up as reddish-brown splotches ... broken across the remote parts of Eastern Russia in the ... MODIS instrument, it is still possible to see the ... features noted below show the devastating number of fires that ...
Breaking Biology News(10 mins):Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... Health Sciences (NIEHS), part of the National Institutes of ... new grants totaling $21.25 million over a five-year period ... prevention and treatment of Parkinson,s disease and other related ... that affects nerve cells, or neurons, in several parts ...
... chairman of Singapore A*STAR,s Biomedical Research Council, has received ... cancer research through his discovery of p53 tumour suppressor ... one of the highest accolades from the Royal Society ... endeavour have made an impact on people,s lives worldwide. ...
... and Washington DC (16 September, 2008) SAGE-Hindawi today announced ... (JDB), the second open access title to be launched in ... The Journal of Dental Biomechanics will provide ... as it relates to dentistry. A growing area of study, ...
Cached Biology News:NIEHS invests $21.25 million to find environmental causes of Parkinson's disease 2NIEHS invests $21.25 million to find environmental causes of Parkinson's disease 3SAGE-Hindawi launch Journal of Dental Biomechanics 2